| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP Research | Officer Level 14 | EVP, Research +1 more
1 company
Eric Swayze is EVP Research at IONS. Eric Swayze's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $16K at current prices.
Historically, Eric Swayze's trades have earned a middling insider score of 67/100 across 24 rated trades. Over a 12-month horizon, 63.2% of those trades were profitable, with an average 12-month return of -5.1%.
The IONS filings lean toward selling, a net 175,425 shares.
Eric Swayze has 46 Form 4 filings on record from January 2020 to October 2026, all as EVP Research at Ionis Pharmaceuticals (IONS), 2020–2026.
The 96 reported transactions were 32 open-market sales, 29 option or other derivative awards, 19 option exercises and 9 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 24 sales worth about $11.1M.
The largest open-market sale was 23,463 shares of IONS at an average $79.12 on January 2, 2026, about $1.9M.
9 of the 18 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 9 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP Research | Sale+OE | 53 | $43.54 | $2,307.56 | -12.0% | - | - | |
| Jun 25, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP Research | Sell10b5-1 | 10,602 | $79.18 | $839,491.80 | -32.8% | -43.9% | - | |
| Feb 13, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP Research | Sell10b5-1 | 15,642 | $81.76 | $1,278,913.96 | -32.8% | -6.1% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sell | 6,179 | $82.93 | $512,446.10 | -11.5% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP Research | Sale+OE | 9,933 | $75.34 | $748,383.09 | -19.0% | -1.4% | - | |
| Jan 2, 2026 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sale+OE10b5-1 | 23,463 | $79.12 | $1,856,324.51 | -43.5% | -6.1% | - | |
| Oct 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sale+OE | 53 | $73.62 | $3,901.93 | -17.2% | +7.9% | -41.2% | |
| Oct 6, 2025 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sell10b5-1 | 6,849 | $69.02 | $472,717.98 | -18.4% | +13.8% | -36.3% | |
| Oct 2, 2025 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sale+OE10b5-1 | 27,114 | $66.16 | $1,793,744.13 | -42.1% | +15.7% | -36.3% | |
| Sep 2, 2025 | IONS Ionis Pharmaceuticals Inc | EVP Research | Sell10b5-1 | 11,130 | $49.67 | $552,861.68 | -23.0% | +42.6% | +6.7% |